September 18, 2019

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(c), Celgene is providing the following information related to the introduction of INREBIC® (fedratinib), approved on August 16, 2019 for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Pursuant to 18 V.S.A. § 4637(d), Celgene has limited the information reported below to that which is in the public domain or publicly available.

1) There are no marketing or pricing plans in the United States or internationally that are in the public domain or publicly available.

   As with the launch of any new medicine, Celgene actively seeks to educate key stakeholders – including physicians, payers and patients – around the medicine's indication(s), efficacy, and safety profile. Generating this awareness for INREBIC® will be a critical component of Celgene's marketing efforts.

   Additionally, as with all of its products, Celgene determined the price of INREBIC® with strong consideration of its benefit to patients, health systems and society and in accordance with Celgene's publicized Pricing Principles that focus on access, value, innovation and flexibility.

2) No information regarding the volume of patients who may be prescribed this drug is in the public domain or publicly available.

3) INREBIC® was granted a Priority Review by the U.S. Food and Drug Administration (FDA) on March 5, 2019.

4) INREBIC® was acquired by Celgene in its purchase of Impact Biomedicines on February 12, 2018 for an upfront payment of $1.1 billion and up to $1.4 billion in contingent payments based on regulatory approval milestones.

Sincerely,

James Kilgallon

Executive Director, Pricing and Contracting Strategy